World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
74
Citations
21695
World Ranking
19371
National Ranking
1015

Ulrich Dührsen publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ulrich Dührsen sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 396 publications — 37th percentile

37% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ulrich Dührsen D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ulrich Dührsen sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 74 D-Index — 4th percentile

4% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ulrich Dührsen is affiliated with the University of Duisburg-Essen in Germany and has contributed extensively to the field of medicine, with a total of 210 publications. Their research primarily focuses on several subfields including pathology and forensic medicine, radiology, nuclear medicine and imaging, oncology, genetics, and pulmonary and respiratory medicine.

Their main research topics include lymphoma diagnosis and treatment, medical imaging techniques and applications, radiomics and machine learning in medical imaging, CNS lymphoma diagnosis and treatment, chronic lymphocytic leukemia research, CAR-T cell therapy research, and acute myeloid leukemia research.

Frequent publication venues for Dührsen's work include:

  • Blood
  • Blood Advances
  • Scientific Reports
  • Leukemia
  • Hematological Oncology

Among recent publications, notable papers include:

  • Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA, 2021, Nature Biotechnology
  • Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index, 2022, Journal of Clinical Oncology
  • Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas, 2022, Cancer Cell
  • Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma, 2021, British Journal of Haematology
  • Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma, 2021, Journal of Clinical Oncology

Collaborations have played a significant role in Dührsen's research output. Frequent co-authors include Andreas Hüttmann, Christine Hanoun, Pieternella J. Lugtenburg, Ronald Boellaard, and Josée M. Zijlstra.

Best Publications

  • A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

    Eva Hoster;Martin Dreyling;Wolfram Klapper;Christian Gisselbrecht

  • Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

    Georg Lenz;Martin Dreyling;Eva Hoster;Bernhard Wörmann

  • Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

    Peter Hillmen;Petra Muus;Ulrich Dührsen;Antonio M. Risitano

  • Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

    Anas Younes;Laurie H. Sehn;Peter Johnson;Pier Luigi Zinzani

  • Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

    Kai Neben;Henk M. Lokhorst;Anna Jauch;Uta Bertsch

  • Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

    Olivier Hermine;Olivier Hermine;Eva Hoster;Jan Walewski;André Bosly

  • Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

    David M. Kurtz;Florian Scherer;Florian Scherer;Michael C. Jin;Joanne Soo

  • A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.

    Walter Fiedler;Rolf Mesters;Heike Tinnefeld;Sonja Loges

  • Acute Myelogenous Leukemia-Induced Sympathetic Neuropathy Promotes Malignancy in an Altered Hematopoietic Stem Cell Niche

    Maher Hanoun;Dachuan Zhang;Toshihide Mizoguchi;Sandra Pinho

  • Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

    Stephan Stilgenbauer;Thorsten Zenz;Dirk Winkler;Andreas Bühler

  • Inflammatory reactions and severe neutropenia in mice lacking the transcriptional repressor Gfi1.

    Holger Karsunky;Hui Zeng;Thorsten Schmidt;Branko Zevnik

  • An Observational Study of Anaemia Management in Patients with NHL Receiving CHOP-14 or -21 (With or Without Rituximab)

    Gregor Verhoef;Hans E Johnsen;Francesca Gaia Rossi;Antonio Salar

  • Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

    Uwe Platzbecker;Jan Moritz Middeke;Katja Sockel;Regina Herbst

  • Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

    Christian Gisselbrecht;Norbert Schmitz;Nicolas Mounier;Devinder Singh Gill

  • Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

    Dieter Hoelzer;Jan Walewski;Hartmut Döhner;Andreas Viardot

  • CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.

    J Dürig;M Naschar;U Schmücker;K Renzing-Köhler

  • ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia

    J Dürig;H Nückel;M Cremer;A Führer

  • Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

    Oliver G. Ottmann;Barbara Wassmann;Heike Pfeifer;Aristoteles Giagounidis

  • Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.

    R Schroers;F Griesinger;L Trümper;D Haase

  • Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

    E Van Den Neste;N Schmitz;N Mounier;D Gill

Frequent Co-Authors

Ludger Klein-Hitpass
Ludger Klein-Hitpass University of Duisburg-Essen
Tarik Möröy
Tarik Möröy University of Montreal
Karl-Heinz Jöckel
Karl-Heinz Jöckel University of Duisburg-Essen
Martin Dreyling
Martin Dreyling Ludwig-Maximilians-Universität München
Ralf Küppers
Ralf Küppers University of Duisburg-Essen
Hartmut Döhner
Hartmut Döhner University of Ulm
Davide Rossi
Davide Rossi European Society for Medical Oncology
Reiner Siebert
Reiner Siebert University of Ulm
Wolfram Klapper
Wolfram Klapper Kiel University
Hubert Schrezenmeier
Hubert Schrezenmeier University of Ulm

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in healthcare careers beyond traditional medical school? There are several flexible and affordable online paths to enter the medical field. For example, earning a pharmacy degree online can help you become a licensed pharmacist, opening doors to clinical and research roles.

If you are more interested in healthcare technology and administration, accredited rhit programs online train you in managing patient records and healthcare information systems.

For those looking for a quicker entry into the medical field, consider a low cost medical coding and billing online program. These programs prepare you for essential roles supporting clinics, hospitals, and insurance companies.

Nursing is another rewarding pathway. The cheapest online fnp program offers an affordable route for nurses to become family nurse practitioners with advanced patient care responsibilities.

Each of these online degrees offers strong job prospects and flexible study options, making them excellent alternatives or complementary pathways to studying medicine in the USA.

Best Scientists Citing Ulrich Dührsen

Trending Scientists

Recently Published Articles